Study of avutometinib, defactinib, and cetuximab for advanced colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of three drugs for people with advanced colorectal cancer that has not responded to standard treatments. The goal is to see if combining these drugs can shrink tumors or slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have advanced colorectal cancer that cannot be removed by surgery and has grown despite previous treatments.
- Your tumor must not have certain genetic mutations (KRAS, NRAS, BRAF V600E, EGFR ectodomain) tested before any anti-EGFR therapy.
- You must have had at least 16 weeks of prior anti-EGFR therapy (cetuximab or panitumumab) and had a complete or partial response before progression.
- You must be in good enough health to get around and care for yourself (ECOG score 0 or 1), and have adequate blood counts, liver, and kidney function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a combination of three drugs (cetuximabβ, envolimab, and mFOLFOX6) can help people with advanced colorectal cancer that has not been treated before. It is for people whose tumors have certain gene markers (RAS/BRAF wild-type and MSS).
This trial tests cetuximab combined with dabrafenib and tislelizumab in people with advanced colorectal cancer that has a BRAF V600E mutation. It’s for cases where the first standard treatment didn’t work or couldn’t be tolerated, aiming to shrink tumors and improve control of the disease.
This trial tests whether the drug ulixertinib, combined with cetuximab (and sometimes encorafenib), can help people with advanced or metastatic colorectal cancer who have already tried EGFR or BRAF-targeted therapy. It aims to find new treatment options for these patients.
This trial tests a combination of three targeted drugs (avutometinib, defactinib, and everolimus) for people whose endometrial cancer has a specific change in the RAS pathway and has not responded to other treatments. The goal is to see if this drug combo can shrink tumors or slow their growth.
This trial is testing a new combination of drugs (envafolimab, cetuxima-β, and chemotherapy) for people with a specific type of advanced colorectal cancer that has not been treated yet. The goal is to see if it is safe and works well.
This trial tests a combination of three drugs (irinotecan liposomes, cetuximab, and vemurafenib) for people with advanced colorectal cancer that has a specific genetic change (BRAF V600E mutation) and did not respond to first treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Hear when a new Advanced Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.